Volume 2 Supplement 1

5th German Conference on Cheminformatics: 23. CIC-Workshop

Open Access

Biomaterialcoatings - a challenging task studied by the molecular fragment dynamics

Journal of Cheminformatics20102(Suppl 1):O14

DOI: 10.1186/1758-2946-2-S1-O14

Published: 04 May 2010

A special and important task in medicinal implant technology is to prevent the material from fouling or make it compatible for tissues by coating the material with functionalized lipid biomolecules. In order to rationalize the design of such new materials structural information about the film is needed. In this presentation we give an account on the investigation of coating of the tetraetherlipid GDNT on a borofluorate surface in different solvents. To gain insights into the dynamic process on the microsecond and micrometer scale we applied our recently developed Molecular Fragment Dynamics method (MFD) [1].

Aside of the size of the system and the duration of the simulation, the challenging task of the investigation lies in the divers chemical functionality of the compounds. The applied MFD algorithm is developed to resolve especially these problems. The MFD algorithm is based on the Dissipative-Particle-Dynamics method (DPD). Whereas in the DPD method the system is divided into different regions of fluid subsystems, the MFD algorithm calculates the interaction of molecular fragments. Consequently, the MFD method is well suited for the molecular modelling simulation of systems having a diverse variety of chemical functionalities thus allowing for investigation of biocoatings, polymers and tensids. Figure 1.

Figure 1

Authors’ Affiliations

(1)
CAM-D Technologies GmbH

References

  1. Ryjkina E, Kuhn H, Rehage H, Müller F, Peggau J: Molecular Dynamic Computer Simulations of Phase Behavior of Non-Ionic Surfactants. Angew Chem Int Ed. 2002, 41: 983-10.1002/1521-3773(20020315)41:6<983::AID-ANIE983>3.0.CO;2-Y.View ArticleGoogle Scholar

Copyright

© Carsten and Kuhn; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.